Proteasome-Regulated ERBB2 and Estrogen Receptor Pathways in Breast Cancer
暂无分享,去创建一个
Christina Yau | C. Benz | C. Yau | B. Hann | G. Scott | John W. Park | Yamei Zhou | C. Marx | John W Park | Byron Hann | Corina Marx | Surita Banwait | Yamei Zhou | Gary K Scott | Christopher C Benz | Surita Banwait
[1] J. Cusack,et al. NPI-0052 Enhances Tumoricidal Response to Conventional Cancer Therapy in a Colon Cancer Model , 2006, Clinical Cancer Research.
[2] T. Hunter,et al. Proteasome inhibitor drugs on the rise. , 2006, Cancer research.
[3] C. Benz,et al. Validated high-throughput screening of drug-like small molecules for inhibitors of ErbB2 transcription. , 2006, Assay and drug development technologies.
[4] D. Esseltine,et al. Bortezomib (VELCADE) in metastatic breast cancer: pharmacodynamics, biological effects, and prediction of clinical benefits. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[5] M. Pino,et al. Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells. , 2006, Cancer research.
[6] D. Sawyer,et al. Heat shock proteins in cancer: chaperones of tumorigenesis. , 2006, Trends in biochemical sciences.
[7] B. Mellado,et al. Differential cellular and molecular effects of bortezomib, a proteasome inhibitor, in human breast cancer cells , 2006, Molecular Cancer Therapeutics.
[8] E. Dees,et al. Targeting the ubiquitin-proteasome pathway in breast cancer therapy. , 2006, Future oncology.
[9] R. Orlowski,et al. The proteasome and proteasome inhibitors in cancer therapy. , 2006, Annual review of pharmacology and toxicology.
[10] Hiroshi Yasui,et al. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. , 2005, Cancer cell.
[11] C. J. Barnes,et al. Growth Factor Regulation of a 26S Proteasomal Subunit in Breast Cancer , 2005, Clinical Cancer Research.
[12] C. Osborne,et al. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu , 1992, Breast Cancer Research and Treatment.
[13] M. Sliwkowski,et al. Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin. , 2004, Molecular biology of the cell.
[14] S. Gillies,et al. Use of Methotrexate-Based Peptide Substrates to Characterize the Substrate Specificity of Prostate-Specific Membrane Antigen (PSMA) , 2004, Cancer biology & therapy.
[15] L. Neckers,et al. Simultaneous inhibition of hsp 90 and the proteasome promotes protein ubiquitination, causes endoplasmic reticulum-derived cytosolic vacuolization, and enhances antitumor activity. , 2004, Molecular cancer therapeutics.
[16] D. Siegel,et al. Regulation of NF-kB in multiple myeloma: therapeutic implications. , 2004, Clinical advances in hematology & oncology : H&O.
[17] C. Sotiriou,et al. Targeting the ubiquitin-proteasome pathway in breast cancer. , 2004, Clinical breast cancer.
[18] J. Vance,et al. The Deacetylase HDAC6 Regulates Aggresome Formation and Cell Viability in Response to Misfolded Protein Stress , 2003, Cell.
[19] J. Ellenberg,et al. Cyclic, proteasome-mediated turnover of unliganded and liganded ERalpha on responsive promoters is an integral feature of estrogen signaling. , 2003, Molecular cell.
[20] Chawnshang Chang,et al. Proteasome Activity Is Required for Androgen Receptor Transcriptional Activity via Regulation of Androgen Receptor Nuclear Translocation and Interaction with Coregulators in Prostate Cancer Cells* , 2002, The Journal of Biological Chemistry.
[21] C. Benz,et al. Transcriptional repression of ErbB2 by histone deacetylase inhibitors detected by a genomically integrated ErbB2 promoter-reporting cell screen. , 2002, Molecular cancer therapeutics.
[22] T. Kohout,et al. Regulation of Receptor Fate by Ubiquitination of Activated β2-Adrenergic Receptor and β-Arrestin , 2001, Science.
[23] Y. Yarden,et al. Sensitivity of Mature ErbB2 to Geldanamycin Is Conferred by Its Kinase Domain and Is Mediated by the Chaperone Protein Hsp90* , 2001, The Journal of Biological Chemistry.
[24] T. Malek,et al. The Proteasome Regulates Receptor-mediated Endocytosis of Interleukin-2* , 2001, The Journal of Biological Chemistry.
[25] A. Goldberg,et al. Proteasome inhibitors: from research tools to drug candidates. , 2001, Chemistry & biology.
[26] B. O’Malley,et al. The 26S Proteasome Is Required for Estrogen Receptor-α and Coactivator Turnover and for Efficient Estrogen Receptor-α Transactivation , 2000 .
[27] B. O’Malley,et al. The 26S proteasome is required for estrogen receptor-alpha and coactivator turnover and for efficient estrogen receptor-alpha transactivation. , 2000, Molecular cell.
[28] J. Cusack,et al. Control of inducible chemoresistance: Enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-κB , 1999, Nature Medicine.
[29] R. Kopito,et al. Aggresomes: A Cellular Response to Misfolded Proteins , 1998, The Journal of cell biology.